trial
as of 2026-07-01Early Psychosis Intervention - Spreading Evidence-based Treatment
NCTId NCT03919760
at a glance
— · Completed
Enrollment 100 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2024-12-23
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
None
Start
2020-01-03
Primary completion
2024-12-23
Eligibility
ALL · 14 Years · 35 Years
Interventions & indications
Drugs
Indications
Affective Disorders, PsychoticSchizophreniform DisordersSchizophrenia Spectrum and Other Psychotic DisordersPsychosisSchizophrenia, ChildhoodSchizoaffective DisorderBipolar I DisorderPsychotic DisordersSchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersFirst Episode PsychosisSchizophrenia
Sponsors
Centre for Addiction and Mental HealthLead Sponsor
Canadian Institutes of Health Research (CIHR)Collaborator
Institute for Clinical Evaluative SciencesCollaborator
North Bay Regional Health CentreCollaborator
Health Sciences NorthCollaborator
Niagara Region Public HealthCollaborator
Lakeridge Health CorporationCollaborator
Canadian Mental Health AssociationCollaborator
Investigators
5
Aristotle N Voineskos, MD, PhDPrincipal Investigator
George Foussias, MD PhD FRCPCPrincipal Investigator
Paul Kurdyak, MD, PhDPrincipal Investigator
Janet Durbin, PhD, MScPrincipal Investigator
Sanjeev Sockalingam, MDPrincipal Investigator
Sites
6 total
Greater Sudbury, CanadaNorth Bay, CanadaOshawa, CanadaThorold, CanadaThunder Bay, CanadaWaterloo, Canada
Facts & assertions
4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2024-12-23
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
indication
indication
investigator